m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG01232)
Name
NKP-1339
Synonyms
197723-00-5; KP-1339; EX-A1916; BCP26252; Z-3126; 1H-indazole; tetrachlororuthenium(1-) sodium salt
    Click to Show/Hide
Status
Phase 1
Structure
3D MOL
2D MOL
Formula
C14H12Cl4N4NaRu
InChI
1S/2C7H6N2.4ClH.Na.Ru/c2*1-2-4-7-6(3-1)5-8-9-7;;;;;;/h2*1-5H,(H,8,9);4*1H;;/q;;;;;;+1;+3/p-4
InChIKey
WVVOCRYXBTVDRN-UHFFFAOYSA-J
PubChem CID
25134754
TTD Drug ID
D08SIT
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Endoplasmic reticulum chaperone BiP (HSPA5)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Endoplasmic reticulum chaperone BiP (HSPA5) is a therapeutic target for NKP-1339. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NKP-1339 through regulating the expression of Endoplasmic reticulum chaperone BiP (HSPA5). [1], [2]
YTH domain-containing family protein 2 (YTHDF2)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Endoplasmic reticulum chaperone BiP (HSPA5) is a therapeutic target for NKP-1339. The YTH domain-containing family protein 2 (YTHDF2) has potential in affecting the response of NKP-1339 through regulating the expression of Endoplasmic reticulum chaperone BiP (HSPA5). [1], [2]
Stress-activated protein kinase JNK1 (JNK1)
Methyltransferase-like 3 (METTL3)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for NKP-1339. The Methyltransferase-like 3 (METTL3) has potential in affecting the response of NKP-1339 through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). [3], [4]
RNA demethylase ALKBH5 (ALKBH5)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Stress-activated protein kinase JNK1 (JNK1) is a therapeutic target for NKP-1339. The RNA demethylase ALKBH5 (ALKBH5) has potential in affecting the response of NKP-1339 through regulating the expression of Stress-activated protein kinase JNK1 (JNK1). [4], [5]
References
Ref 1 METTL3 mediates osteoblast apoptosis by regulating endoplasmic reticulum stress during LPS-induced inflammation. Cell Signal. 2022 Jul;95:110335. doi: 10.1016/j.cellsig.2022.110335. Epub 2022 Apr 21.
Ref 2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1879).
Ref 3 METTL3 regulates alternative splicing of MyD88 upon the lipopolysaccharide-induced inflammatory response in human dental pulp cells. J Cell Mol Med. 2018 May;22(5):2558-2568. doi: 10.1111/jcmm.13491. Epub 2018 Mar 4.
Ref 4 c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014). Expert Opin Ther Pat. 2015;25(8):849-72. doi: 10.1517/13543776.2015.1039984. Epub 2015 May 19.
Ref 5 Post-translational modification of RNA m6A demethylase ALKBH5 regulates ROS-induced DNA damage response. Nucleic Acids Res. 2021 Jun 4;49(10):5779-5797. doi: 10.1093/nar/gkab415.